Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

ConditionAsthma
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age10-80
SponsorGelb, Arthur F., M.D.

About this trial

The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whether intrinsic small airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow limitation. The investigators are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma.

Eligibility criteria

Qualifiers

Current non-smoking (<10 pack yr smoking history)

Stable, treated asthmatics

Age 10-80 yr

post 180ug albuterol by MDI: FEV 1/FVC < 70% and FEV 1 <80% predicted

Disqualifiers

Pregnancy

Trial design

Treatments tested in this trial

  • fluticasone/salmeterol in all asthmatics
  • budesonide/formoterol or fluticasone/salmeterol in all asthmatics

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators